2 Aronow WS. Etiology, pathophysiology, and treatment of atrial fibrillation: part 1 [J]. Cardiol Rev, 2008, 16(4): 181-188.
[3]
3 Olshansky B, Rosenfeld LE, Warner AL, et al. The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation[J]. J Am Coll Cardiol, 2004, 43(7): 1201-1208.
[4]
4 Berisso MZ, Fabbri G, Gonzini L, et al. Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists: Antithrombotic Agents in Atrial Fibrillation (ATA-AF) survey[J]. J Cardiovasc Med (Hagerstown), 2014, 15(8): 626-635.
[5]
5 Lip GY, Da LE. Stroke prevention in atrial fibrillation: a systematic review[J]. JAMA, 2015, 313(19): 1950-1962.
[6]
6 January CT, Wann LS, Alpert JS, et al. College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014, 64(21): e1-e76.
10 Rogenstein C, Kelly AM, Mason S, et al. An international view of how recent-onset atrial fibrillation is treated in the emergency department[J]. Acad Emerg Med, 2012, 19(11): 1255-1260.
[11]
11 Kalus JS. Pharmacotherapeutic decision-making for patients with atrial fibrillation[J]. Am J Health Syst Pharm, 2010, 67(9 Suppl 5): S17-S25.
[12]
12 Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the Aristotle trial[J]. J Am Coll Cardiol, 2014, 64(15): 1541-1550.
[13]
13 Martindale JL, Desouza IS, Silverberg M, et al. β-Blockers versus calcium channel blockers for acute rate control of atrial fibrillation with rapid ventricular response: a systematic review[J]. Eur J Emerg Med, 2015, 22(3): 150-154.
[14]
14 Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study[J]. J Am Coll Cardiol, 1991, 18(4): 891-897.
[15]
15 Siu CW, Lau CP, Lee WL, et al. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation[J]. Crit Care Med, 2009, 37(7): 2174-2179.
[16]
16 Personett HA, Smoot DL, Stollings JL, et al. Intravenous metoprolol versus diltiazem for rate control in noncardiac, nonthoracic postoperative atrial fibrillation[J]. Ann Pharmacother, 2014, 48(3): 314-319.
[17]
17 Demircan C, Cikriklar HI, Engindeniz Z, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation[J]. Emerg Med J, 2005, 22(6): 411-414.
[18]
18 Lee J, Kim K, Lee CC, et al. Low-dose diltiazem in atrial fibrillation with rapid ventricular response[J]. Am J Emerg Med, 2011, 29(8): 849-854.
